Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358137 | 0.90 | SIGMAR1 (0.81) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL8260488 | 0.85 | SIGMAR1 (0.72) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL3583338 | 0.85 | HPGD (0.73) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL23140495 | 0.83 | SIGMAR1 (0.76) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL4505138 | 0.83 | SIGMAR1 (0.70) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL2538732 | 0.82 | HPGD (0.76) | HPGDALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL13600346 | 0.81 | HPGD (0.70) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL1256167 | 0.81 | SIGMAR1 (0.68) | SIGMAR1HPGDALDH1A1RXFP1CCNC | |
| SCHEMBL2336859 | 0.81 | SIGMAR1 (0.68) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 | |
| SCHEMBL5074802 | 0.81 | SIGMAR1 (0.68) | SIGMAR1HPGDMKNK1MKNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047165-A | A kind of benzoate compounds and preparation method and application | 天津科技大学 | 2018-05-18 | — | — | CN | claimed |
| US-4505913-A | Substituted anthranilamides and pharmaceutical preparations containing these compounds | CIBA-GEIGY CORPORATION (US) | 1985-03-19 | — | — | US | claimed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| EP-3455227-A1 | OXABOROLE ESTERS AND USES THEREOF | Anacor Pharmaceuticals, Inc (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-108047165-A | A kind of benzoate compounds and preparation method and application | 天津科技大学 | 2018-05-18 | — | — | CN | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| CN-101267815-A | metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-6579889-B2 | Alzheier's diseases; antiallergens; vision defects; antihistamines; skin disorders | MERCK & CO., INC. | 2003-06-17 | — | — | US | disclosed |
| US-6403584-B1 | CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020019419-A1 | Substituted isonipecotyl derivatives as inhibitors of cell adhesion | MERCK & CO., INC. | 2002-02-14 | — | — | US | disclosed |
| US-4505913-A | Substituted anthranilamides and pharmaceutical preparations containing these compounds | CIBA-GEIGY CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| US-4041032-A | ANTIEMATICS, GASTRIC MOTILITY STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | SIGMAR1 2991/4885HPGD 775/4885MKNK1 2668/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | SIGMAR1 1855/4885HPGD 2258/4885MKNK1 4309/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | SIGMAR1 1855/4885HPGD 2258/4885MKNK1 4309/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | SIGMAR1 1855/4885HPGD 2258/4885MKNK1 4309/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | SIGMAR1 1855/4885HPGD 2258/4885MKNK1 4309/4885 |
| US-20020019419-A1 | Substituted isonipecotyl derivatives as inhibitors of cell adhesion | VCAM1, ICAM1, CD4 | SIGMAR1 4705/4885HPGD 2889/4885MKNK1 716/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | SIGMAR1 1855/4885HPGD 2258/4885MKNK1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.